Testicular cancer · 13 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Chlorambucil, Dactinomycin, Methotrexate Variant #01 | — | R 42 754 | 25d | — | — | — | — | — |
M-TIP Variant #01 | — | R 13 083 | — | — | — | — | — | — |
VIP Variant #01 | — | R 10 535 | 21d | — | — | — | — | — |
VAB-6 Variant #01 | — | R 9 949 | 28d | — | — | — | — | — |
Cisplatin and Etoposide (EP) Variant #01 | — | R 4 264 | 42d | ~5.0 mo | ~10.2 mo | ~4 | ~R 17 056 PFS proxy · indirect | 13 |
PVeBV Variant #01 | — | R 3 148 | 21d | — | — | — | — | — |
CISCA/VB Variant #01 | — | R 2 437 | 21d | — | — | — | — | — |
Accelerated BEP Variant #01 | — | R 2 244 | 14d | — | — | — | — | — |
BEP Variant #01 | — | R 2 244 | 21d | — | — | — | — | — |
C-BOP Variant #01 | — | R 1 642 | 14d | — | — | — | — | — |
Bleomycin and Vinblastine Variant #01 | — | R 1 473 | 35d | — | — | — | — | — |
BVP Variant #01 | — | R 1 107 | 28d | — | — | — | — | — |
Bleomycin and Vincristine (BO) Variant #01 | — | R 327 | 14d | — | — | — | — | — |
13 of 13 regimens shown